Short Cycle, Intermittent Therapy: A Valuable Option in Selected, Virologically Suppressed People Living with HIV

The use of long-acting antiretroviral regimens will not be suitable for all people living with HIV for various reasons (previous virological failure with drugs of the same class, side effects, logistic difficulties, and costs). We think that short-cycle therapies could represent a feasible and valuable option for antiretroviral treatment optimization in selected individuals. So here we review clinical evidence about efficacy of short-cycle therapy in suppressed HIV-infected patients.

Automated summary

Long-acting antiretroviral regimens may not be suitable for all HIV patients, and short-cycle therapy could be a feasible option for optimizing antiretroviral treatment in selected individuals. This review examines the clinical evidence of efficacy in suppressed HIV-infected patients.